載入...
PROFILE 1014: lessons for the new era of lung cancer clinical research
PROFILE 1014 compared crizotinib to up to six cycles of standard platinum-pemetrexed chemotherapy as the first line treatment of advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). Overall, PROFILE 1014 has taught us many valuable lessons about the natural history...
Na minha lista:
| 發表在: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AME Publishing Company
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4630507/ https://ncbi.nlm.nih.gov/pubmed/26629438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.05.02 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|